Allon’s focus is developing central nervous system therapies. Allon’s drug candidates have been shown to work at the cellular level to protect or shield neurons from injury.
Allon’s human clinical trials and animal studies show that davunetide reduces the neurodegenerative “tangles” pathology and also increases memory function.
Allon’s lead drug davunetide, is proceeding in a fully enrolled pivotal Phase 2/3 clinical trial in an orphan indication, progressive supranuclear palsy (PSP), under an SPA with the FDA.
